Differential response to roflumilast in patients with chronic obstructive pulmonary disease : real-world evidence
2024 Journal of Thoracic Disease. All rights reserved..
Background: Roflumilast is effective in reducing acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) at high risk of severe exacerbation. Clinical traits related to the benefits of roflumilast need to be evaluated in patients with COPD.
Methods: A longitudinal observational study in patients newly diagnosed with COPD was conducted using claims data from the Health Insurance Review and Assessment Service in South Korea from 2012-2020 after a 2-year washout period. The primary outcome was to estimate the ratio of hazard ratio (RHR) of roflumilast for moderate-to-severe exacerbation in prespecified subgroups. A time-dependent Cox regression model was used to estimate the hazard ratio (HR) for moderate-to-severe exacerbations.
Results: Among 823,862 patients with COPD, 0.6% used roflumilast. The adjusted HR of roflumilast for moderate-to-severe exacerbations was reduced when treated for ≥3 months (RHR =0.558). Interaction effects of the variables on the HR of roflumilast for moderate-to-severe exacerbation were identified. The adjusted HR of roflumilast for moderate-to-severe exacerbation was significantly reduced in several subgroups: older age (65 years > age ≥50 years, RHR =0.838; age ≥65 years, RHR =0.818), a higher Charlson comorbidity index (1, RHR =0.832; 2, RHR =0.798; ≥3, RHR =0.790), history of exacerbation (RHR =0.886), bronchiectasis (RHR =0.774), chronic bronchitis (RHR =0.793), inhaled therapy [mono-bronchodilator, RHR =0.824; inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA), RHR =0.591; LABA/long-acting muscarinic antagonist (LAMA), RHR =0.822; ICS/LABA/LAMA, RHR =0.570], methylxanthine (RHR =0.853), and statin (RHR =0.888).
Conclusions: The benefit of roflumilast in moderate-to-severe exacerbations was estimated to be greater in specific subgroups of patients with COPD. Personalised approaches to roflumilast based on clinical phenotypes would be effective for COPD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of thoracic disease - 16(2024), 2 vom: 29. Feb., Seite 1338-1349 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Hyun Woo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic obstructive pulmonary disease (COPD) |
|---|
| Anmerkungen: |
Date Revised 21.03.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/jtd-23-1129 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369946782 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369946782 | ||
| 003 | DE-627 | ||
| 005 | 20240322000953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/jtd-23-1129 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369946782 | ||
| 035 | |a (NLM)38505074 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Hyun Woo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential response to roflumilast in patients with chronic obstructive pulmonary disease |b real-world evidence |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2024 Journal of Thoracic Disease. All rights reserved. | ||
| 520 | |a Background: Roflumilast is effective in reducing acute exacerbation in patients with chronic obstructive pulmonary disease (COPD) at high risk of severe exacerbation. Clinical traits related to the benefits of roflumilast need to be evaluated in patients with COPD | ||
| 520 | |a Methods: A longitudinal observational study in patients newly diagnosed with COPD was conducted using claims data from the Health Insurance Review and Assessment Service in South Korea from 2012-2020 after a 2-year washout period. The primary outcome was to estimate the ratio of hazard ratio (RHR) of roflumilast for moderate-to-severe exacerbation in prespecified subgroups. A time-dependent Cox regression model was used to estimate the hazard ratio (HR) for moderate-to-severe exacerbations | ||
| 520 | |a Results: Among 823,862 patients with COPD, 0.6% used roflumilast. The adjusted HR of roflumilast for moderate-to-severe exacerbations was reduced when treated for ≥3 months (RHR =0.558). Interaction effects of the variables on the HR of roflumilast for moderate-to-severe exacerbation were identified. The adjusted HR of roflumilast for moderate-to-severe exacerbation was significantly reduced in several subgroups: older age (65 years > age ≥50 years, RHR =0.838; age ≥65 years, RHR =0.818), a higher Charlson comorbidity index (1, RHR =0.832; 2, RHR =0.798; ≥3, RHR =0.790), history of exacerbation (RHR =0.886), bronchiectasis (RHR =0.774), chronic bronchitis (RHR =0.793), inhaled therapy [mono-bronchodilator, RHR =0.824; inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA), RHR =0.591; LABA/long-acting muscarinic antagonist (LAMA), RHR =0.822; ICS/LABA/LAMA, RHR =0.570], methylxanthine (RHR =0.853), and statin (RHR =0.888) | ||
| 520 | |a Conclusions: The benefit of roflumilast in moderate-to-severe exacerbations was estimated to be greater in specific subgroups of patients with COPD. Personalised approaches to roflumilast based on clinical phenotypes would be effective for COPD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic obstructive pulmonary disease (COPD) | |
| 650 | 4 | |a cohort study | |
| 650 | 4 | |a exacerbation | |
| 650 | 4 | |a population groups | |
| 650 | 4 | |a roflumilast | |
| 700 | 1 | |a Sun, Jiyu |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hyo-Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jung-Kyu |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Tae Yeon |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, Eun Young |e verfasserin |4 aut | |
| 700 | 1 | |a Rhee, Chin Kook |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Deog Kyeom |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic disease |d 2010 |g 16(2024), 2 vom: 29. Feb., Seite 1338-1349 |w (DE-627)NLM219116938 |x 2072-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:2 |g day:29 |g month:02 |g pages:1338-1349 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/jtd-23-1129 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 2 |b 29 |c 02 |h 1338-1349 | ||